Musto, P., Salmanton‐García, J., Sgherza, N., Bergantim, R., Farina, F., Glenthøj, A. ... Pagano, L. (2024). Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry. Hematological Oncology, 42. (1). doi: 10.1002/hon.3240
Musto, Pellegrino, et al. "Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry." Hematological Oncology, vol. 42, br. 1, 2024. https://doi.org/10.1002/hon.3240
Musto, Pellegrino, Jon Salmanton‐García, Nicola Sgherza, Rui Bergantim, Francesca Farina, Andreas Glenthøj, Guldane Cengiz Seval, et al. "Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry." Hematological Oncology 42, br. 1 (2024). https://doi.org/10.1002/hon.3240
Musto, P., et al. (2024) 'Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry', Hematological Oncology, 42(1). doi: 10.1002/hon.3240
Musto P, Salmanton‐García J, Sgherza N, Bergantim R, Farina F, Glenthøj A, i sur.. Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry. Hematological Oncology [Internet]. 2024. [pristupljeno 01.12.2024.];42(1). doi: 10.1002/hon.3240
P. Musto, et al., "Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry", Hematological Oncology, vol. 42, br. 1, 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:365228. [Citirano: 01.12.2024.]